Faculty, Staff and Student Publications
Publication Date
7-2-2024
Journal
Molecular Cancer Therapeutics
DOI
10.1158/1535-7163.MCT-23-0471
PMID
38641411
PMCID
PMC11217730
PubMedCentral® Posted Date
April 2024
PubMedCentral® Full Text Version
Post-print
Abstract
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating the comparison of different studies and determination of whether a PDX experiment has produced evidence needed to consider a new therapy promising. We present consensus recommendations for assessment of PDX growth and antitumor activity, providing public access to a suite of tools for in vivo growth analyses. We expect that harmonizing PDX study design and analysis and assessing a suite of analytical tools will enhance information exchange and facilitate identification of promising novel therapies and biomarkers for guiding cancer therapy.
Keywords
Humans, Animals, Xenograft Model Antitumor Assays, Neoplasms, National Cancer Institute (U.S.), United States, Mice, Antineoplastic Agents, Consensus
Published Open-Access
yes
Recommended Citation
Meric-Bernstam, Funda; Lloyd, Michael W; Koc, Soner; et al., "Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations" (2024). Faculty, Staff and Student Publications. 1631.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/1631
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons